image credit: Pexels

Lilly gets FDA OK for Alzheimer’s drug, cites cost advantage

July 3, 2024


The US regulator has cleared donanemab as Kisunla for use in patients with mild cognitive impairment or the mild dementia stage of Alzheimer’s with confirmed amyloid plaques, becoming the third drug in the class after Eisai/Biogen’s short-lived Aduhelm (aducanumab) and current rival Leqembi (lecanemab).

The Alzheimer’s Association hailed the development, saying that having multiple treatments available will raise the onus on health systems to carry out early detection and diagnosis.

Read More on Pharmaphorum